The US FDA’s newest expedited designation, Regenerative Medicine Advance Therapy (RMAT) status for certain biologics, has subtly different standards than the agency’s popular breakthrough therapy designation (BTD).
The graphic below highlights similarities and differences in the eligibility and evidentiary criteria and timelines for the two expedited regulatory pathways.